ABI-009 (nab-sirolimus)在晚期恶性血管周围上皮样细胞肿瘤中的表达
合集下载
相关主题
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Disclosures
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Malignant Perivascular Epithelioid Cell tumor (PEComa)
Safety Summary, Treatment-related Adverse Events
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Slide 8
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Preliminary Results of Registrational trial: AMPECT <br />nab-Sirolimus in Advanced Malignant PEComa<br />Conclusions
ABI-009 (பைடு நூலகம்ab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase 2 Registration Trial
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
ABI-009 (nab-Sirolimus)
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
AMPECT: nab-Sirolimus in Advanced Malignant PEComa<br />Phase 2 Registrational Open-label Multicenter Study Design
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Thank you to the patients and families, and to the study teams!
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Duration of Response, Time to Response,<br />Progression-free Survival
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Mutational Analysis and Biomarkers <br />Efficacy vs TSC1/TSC2 mutations/deletions by NGS and pS6 by IHC
Response to nab-Sirolimus
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Response to nab-Sirolimus
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Baseline Demographics and Characteristics<br />Enrollment is closed, study is ongoing
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Disclosures
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Malignant Perivascular Epithelioid Cell tumor (PEComa)
Safety Summary, Treatment-related Adverse Events
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Slide 8
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Preliminary Results of Registrational trial: AMPECT <br />nab-Sirolimus in Advanced Malignant PEComa<br />Conclusions
ABI-009 (பைடு நூலகம்ab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase 2 Registration Trial
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
ABI-009 (nab-Sirolimus)
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
AMPECT: nab-Sirolimus in Advanced Malignant PEComa<br />Phase 2 Registrational Open-label Multicenter Study Design
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Thank you to the patients and families, and to the study teams!
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Duration of Response, Time to Response,<br />Progression-free Survival
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Mutational Analysis and Biomarkers <br />Efficacy vs TSC1/TSC2 mutations/deletions by NGS and pS6 by IHC
Response to nab-Sirolimus
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Response to nab-Sirolimus
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Presented By Andrew Wagner at 2019 ASCO Annual Meeting
Baseline Demographics and Characteristics<br />Enrollment is closed, study is ongoing
Presented By Andrew Wagner at 2019 ASCO Annual Meeting